Adults 18 to 80, any sex, with Generalized Pustular Psoriasis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear)Primary· Week 4
The Generalized Pustular Psoriasis Physician's Global Assessment (GPPPGA) is a physician-based assessment of the overall disease severity of GPP at the time of evaluation (specifically pustules, erythema, and scaling/crusting of pustular psoriasis lesions). The GPPPGA is graded on a 5-point scale, ranging from 0 (clear) to 4 (severe).
GPPPGA Scale: 0 = Clear, 1 = Almost clear, 2 = Mild, 3 = Moderate, 4 = Severe.
Group
Value
95% CI
Imsidolimab 750 mg
8
8.27 – 70.57
Imsidolimab 300 mg
8
8.66 – 71.47
Placebo
2
NA – NA
Percentage of Patients Achieving a PRS Score of 0 (Clear) or 1 (Almost Clear)Secondary· Week 1
The Pustulation Rating Scale (PRS) is is a physician-based assessment of the severity of GPP pustulation. Pustulation is graded on a 5-point scale, ranging from 0 (clear) to 4 (severe).
PRS Scale: 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate, 4 = Severe.
Group
Value
95% CI
Imsidolimab 750 mg
6
-3.74 – 57.07
Imsidolimab 300 mg
10
24.91 – 81.76
Placebo
2
NA – NA
Adverse events — posted to ClinicalTrials.gov
Time frame: All Adverse Events (AEs) were collected from signature of the informed consent up to the final Safety Follow-up Visit (Week 12) regardless of seriousness or relationship to investigational product..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Generalized Pustular Psoriasis
Currently open trials in the same condition.
NCT06477536 — Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis
· Phase 2, PHASE3
· recruiting
NCT06323356 — A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
· Phase 3
· active not recruiting
NCT06295692 — A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
· Phase 3
· active not recruiting
NCT06013969 — A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeate
· Phase 4
· active not recruiting
NCT03886246 — Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Too
· Phase 2
· active not recruiting
Other Vanda Pharmaceuticals trials
Trials by the same sponsor.
NCT07446439 — A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
· Phase 3
· recruiting
NCT06804603 — A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
· Phase 2
· completed
NCT06701396 — Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant
· Phase 3
· recruiting
NCT06494397 — Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions
· Phase 1
· completed
NCT05903924 — Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
· Phase 3
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanda Pharmaceuticals
Last refreshed: 17 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05352893.